It is a non-surgical energy-based procedure using a medical radiofrequency device. A suitable internal or external applicator delivers controlled RF energy to the agreed vulval or vaginal area. Tissue resistance converts the energy into heat. Devices, parameters and intended uses differ, so vaginal RF is not one standardised treatment.

Yes. WHC offers private consultation and, where suitable, doctor-delivered intimate and vaginal radiofrequency treatment. Consultation is required before treatment so the concern, anatomy, alternatives, risks, proposed areas and course can be reviewed.

Doctors deliver the treatment at WHC. The treatment plan is also assessment-led, with device suitability, medical history, examination findings and consent reviewed before RF is performed.

WHC does not promote one manufacturer or commercial affiliation. We use medical CE-marked equipment selected according to the intended treatment area, applicable documentation, UK requirements and individual plan. The proposed device and treatment approach should be explained before consent.

CE marking shows that the manufacturer has followed the applicable conformity route for the device and its stated intended purpose. CE-marked medical devices may be accepted on the Great Britain market under current UK arrangements when the relevant requirements are met. A CE mark does not prove that every advertised benefit is established or that the device is suitable for every woman or anatomical area.

WHC may consider all clinically appropriate external and internal areas, including selected vulval, labial, vestibular, introitus and vaginal tissues. The final area depends on the concern, examination, device applicator, manufacturer instructions and clinical judgement. Not every device or applicator is suitable for every area.

After the plan and consent are confirmed, the area is prepared and the doctor uses the appropriate internal and/or external RF applicator. Controlled energy is delivered according to the device protocol while treatment parameters and comfort are monitored. The exact appointment length depends on the areas treated and plan.

No. RF uses electromagnetic energy to generate controlled heat; CO₂ or erbium lasers use light energy and interact with tissue differently. Applicators, protocols, tissue effects, evidence and risks are not identical. Neither treatment should be presented as universally better.

No. Standard non-ablative vaginal RF does not involve surgical cutting, stitches or injection of filler, PRP, skin booster, polynucleotide or exosome material. It remains a medical energy-based procedure and is not risk-free.

Women commonly describe warmth and may experience pressure, sensitivity or discomfort. Experience varies by device, area, settings and individual sensitivity. WHC does not describe the procedure as universally painless; tell the doctor immediately if treatment feels excessively hot or painful.

Many women return to gentle normal activities after treatment. Temporary warmth, redness, tenderness, swelling, discharge, spotting or irritation can occur. You may be asked to avoid intercourse, tampons, swimming, hot baths, saunas, harsh products and strenuous exercise for a short period. Follow the written aftercare provided for your plan.

WHC commonly offers a course of four, but treatment varies from woman to woman. The number and spacing of sessions depend on assessment, the medical device protocol, treatment areas, response and clinical judgement. The optimal regimen is not established across all RF devices and indications.

The doctor face-to-face consultation is £150. A single radiofrequency treatment session is £699, and a course of four is £2,300. The course may vary after assessment. Check the current WHC pricing page before booking in case fees change.

Similar concerns can have different causes and may need menopause care, pelvic-floor treatment, investigation or another procedure. Consultation allows the doctor to review history, examine where appropriate, identify red flags, explain alternatives and decide whether RF and the proposed areas are suitable. Consultation does not guarantee treatment.

Outcomes vary and cannot be guaranteed. Published studies use different devices, protocols and outcomes, with mixed findings. Some women report changes in comfort, dryness, perceived laxity or sexual-function scores; others may notice little or no meaningful improvement. RF should not be presented as permanent rejuvenation.

No. “Radiofrequency vaginal tightening” is a common search and marketing phrase, but it is not a guaranteed result. RF does not surgically tighten the vagina, repair prolapse or strengthen pelvic-floor muscles. Perceived laxity needs assessment because the cause affects which treatment, if any, is appropriate.

It may be discussed with selected women, but it is not standard first-line treatment for genitourinary syndrome of menopause. NICE guidance includes vaginal oestrogen, moisturisers and lubricants, with other options considered according to individual circumstances. Do not stop prescribed treatment without medical advice.

RF has been studied for urinary symptoms, but evidence varies and it is not a substitute for continence assessment. NICE recommends supervised pelvic-floor muscle training as first-line treatment for stress or mixed urinary incontinence. Leakage may also require bladder, pelvic-floor, prolapse or specialist review.

RF may be discussed after appropriate postnatal recovery in selected women. Treatment is not a substitute for assessing pelvic-floor injury, prolapse, scar pain, infection, breastfeeding-related hormone change or other postpartum concerns. Timing and suitability are decided during consultation.

Potential effects include warmth, tenderness, redness, swelling, irritation, discharge or spotting. Infection, burns, blistering, scarring, altered sensation, pain during intercourse and persistent pain have also been reported with vaginal energy-based devices. The true long-term risk profile is not fully established.

Treatment may be unsuitable or delayed with pregnancy, recent childbirth, active genital or urinary infection, unexplained bleeding or pain, suspicious vulval or vaginal lesions, current pelvic malignancy, recent pelvic surgery, previous pelvic radiotherapy, certain implanted electrical devices or another device-specific contraindication. This is not a complete list; individual assessment and the device instructions govern suitability.

Sometimes, but only as a planned, staged pathway after assessment. RF may be considered alongside menopause care, pelvic-floor support, laser, PRP, skin boosters, polynucleotides or another treatment. Combination treatment is not automatically better, and the safest sequence and interval depend on the procedures and clinical plan.

Evidence is developing and mixed. Some randomised and comparative studies report improvements in selected outcomes, while a 2024 randomised trial found low-energy RF was not superior to gel and lacked statistical power. Studies differ in device, participants, comparator, course and follow-up. Long-term safety, durability and the optimal regimen remain uncertain.